In Vitro Inhibition of SARS-CoV-2 Infection by Bromhexine hydrochloride

The world is enduring the SARS CoV-2 pandemic, and although extensive research has been conducted on the issue, only a few antivirals have been approved to treat patients with COVID-19. Bromhexine hydrochloride was previously identified as a potent inhibitor of TMPRSS2, an essential protease for ACE-2 virus receptor interactions. In the present study, we investigated whether bromhexine treatment could reduce SARS CoV-2 replication in vitro. To evaluate bromhexine’s effectiveness against SARS COV-2 infection, viral load was measured using Caco-2 cell lines expressing TMPRSS2. Our molecular docking results indicate that bromhexine displays an affinity with the active site of TMPRSS2. The drug significantly inhibited SARS CoV-2, both parental and P1 variant strains, infection in the Caco-2 cell line, reducing about 40% of SARS-CoV-2 entrance and about 90% of viral progeny in the supernatant 48h post-infection. Furthermore, bromhexine did not exhibit any direct virucidal activity on SARS CoV-2. In conclusion, bromhexine hydrochloride efficiently disrupts SARS CoV-2 infection in vitro and has the potential to become an effective antiviral agent in COVID-19 treatment.

[1]  A. Konradi,et al.  Bromhexine Hydrochloride Prophylaxis of COVID-19 for Medical Personnel: A Randomized Open-Label Study , 2021, medRxiv.

[2]  F. Neipel,et al.  SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation , 2021, Journal of Virology.

[3]  Nuno R. Faria,et al.  Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence , 2021, The Lancet.

[4]  Wenwu Zhang,et al.  Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study , 2020, Clinical and translational science.

[5]  L. Tang,et al.  Re-recognizing bromhexine hydrochloride: pharmaceutical properties and its possible role in treating pediatric COVID-19 , 2020, European journal of clinical pharmacology.

[6]  Y. Xin,et al.  ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 , 2020, Biomedicine & Pharmacotherapy.

[7]  N. Lopes,et al.  Tenofovir Disoproxil Fumarate: New Chemical Developments and Encouraging in vitro Biological Results for SARS-CoV-2 , 2020, Journal of the Brazilian Chemical Society.

[8]  S. Safiri,et al.  Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial , 2020, BioImpacts : BI.

[9]  M. Hall,et al.  An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 , 2020, bioRxiv.

[10]  D. Fremont,et al.  Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. , 2020, SSRN.

[11]  S. Lindstrom,et al.  US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Emerging infectious diseases.

[12]  I. Berindan‐Neagoe,et al.  Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2 , 2020, Pharmacological Research.

[13]  G. Corsini,et al.  Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection , 2020, Pharmacological Research.

[14]  Vineet D. Menachery,et al.  Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[15]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[16]  Ling Wang,et al.  Bromhexine elevates REP2 expression to stimulate secretion from human primary conjunctiva fornix epithelial cells , 2020, FEBS letters.

[17]  P. Marcato,et al.  Assessing the cytotoxic potential of glycoalkaloidic extract in nanoparticles against bladder cancer cells , 2019, The Journal of pharmacy and pharmacology.

[18]  Yukiko Shimizu,et al.  TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection , 2019, Journal of Virology.

[19]  The UniProt Consortium,et al.  UniProt: a worldwide hub of protein knowledge , 2018, Nucleic Acids Res..

[20]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[21]  Yoshimasa Tanaka,et al.  TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections , 2017, Biochimie.

[22]  P. Nelson,et al.  The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. , 2014, Cancer discovery.

[23]  Yang Zhang,et al.  Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. , 2011, Biophysical journal.

[24]  K. Schughart,et al.  TMPRSS2 and TMPRSS4 Facilitate Trypsin-Independent Spread of Influenza Virus in Caco-2 Cells , 2010, Journal of Virology.

[25]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[26]  F. Fang.  HPLC-MS assay for the determination of bromhexine in human plasma and application to bioequivalence studies , 2008 .

[27]  Manfred J. Sippl,et al.  Thirty years of environmental health research--and growing. , 1996, Nucleic Acids Res..

[28]  P. Nelson,et al.  Phenotypic Analysis of Mice Lacking the Tmprss2-Encoded Protease , 2006, Molecular and Cellular Biology.

[29]  A. Zijlstra,et al.  The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells. , 2005, The Biochemical journal.

[30]  N. Durán,et al.  Dehydrocrotonin and its beta-cyclodextrin complex: cytotoxicity in V79 fibroblasts and rat cultured hepatocytes. , 2005, European journal of pharmacology.

[31]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[32]  X. Tu,et al.  [Determination of bromhexine in plasma by gas chromatography-electron capture detection and pharmacokinetic studies]. , 2000, Se pu = Chinese journal of chromatography.

[33]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[34]  E. Borenfreund,et al.  A simple quantitative procedure using monolayer cultures for cytotoxicity assays (HTD/NR-90) , 1985 .

[35]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .